60 results on '"Ratziu, Vlad"'
Search Results
2. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
3. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.
4. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
5. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study
6. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
7. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.
8. RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease.
9. An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project.
10. Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
11. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
12. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
13. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
14. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension.
15. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients
16. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
17. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
18. Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
19. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
20. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
21. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
22. Relationship Among Fatty Liver, Specific and Multiple‐Site Atherosclerosis, and 10‐Year Framingham Score.
23. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.
24. Reply: More questions than answers--Response to the POP-NEXT project.
25. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
26. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
27. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
28. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
29. A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
30. Impact of steatosis and inflammation definitions on the performance of NASH tests.
31. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients.
32. Reply.
33. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles.
34. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
35. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
36. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
37. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.
38. Endpoints and clinical trial design for nonalcoholic steatohepatitis.
39. Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues.
40. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
41. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious.
42. FAS promoter polymorphisms correlate with activity grade in hepatitis C patients.
43. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.
44. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
45. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.
46. Expression of connective tissue growth factor in experimental rat and human liver fibrosis.
47. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency.
48. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
49. Diagnostic value of FibroTest with normal serum aminotransferases.
50. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.